Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 - Seite 2

Title:	RTK Signaling and WT RAS Activity as Vulnerabilities in Tumors with Acquired Resistance to GDP-State Selective KRASG12C Inhibitors in Preclinical Models
Lead RevMed Co-Author:	Harshit Shah, Ph.D.
Abstract Number:	1924/2
Session:	Drug Resistance 2: RAS GTPase
Date/Time:	9:00 a.m. – 12:30 p.m. PT on April 8, 2024
Title:	Resistance to RAS-GTP Inhibition in Models of Pancreatic Ductal Adenocarcinoma Arises Downstream of RAS Effectors
Lead RevMed Co-Author:	Jingjing Jiang, Ph.D.
Abstract Number:	1927/5
Session:	Drug Resistance 2: RAS GTPase
Date/Time:	9:00 a.m. – 12:30 p.m. PT on April 8, 2024

Additional information on the AACR Annual Meeting 2024 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2024/

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).

CONTACT: Media & Investor Contact
Erin Graves
650-779-0136
[e-mail]